Scarica l'app Stockscreener
1.915
2.68%
0.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNGX Giù?
Forum
Previsione
Precedente Chiudi:
$1.865
Aprire:
$1.83
Volume 24 ore:
1.52M
Relative Volume:
1.12
Capitalizzazione di mercato:
$207.57M
Reddito:
$42.51M
Utile/perdita netta:
$-116.49M
Rapporto P/E:
-1.7098
EPS:
-1.12
Flusso di cassa netto:
$-120.82M
1 W Prestazione:
+27.67%
1M Prestazione:
+30.27%
6M Prestazione:
-51.15%
1 anno Prestazione:
-72.99%
Intervallo 1D:
$1.79
$2.04
Intervallo di 1 settimana:
$1.47
$3.00
Portata 52W:
$1.03
$12.02
Tango Therapeutics Inc Stock (TNGX) Company Profile
Nome
Tango Therapeutics Inc
Settore
Industria
Telefono
(857) 320-4900
Indirizzo
201 BROOKLINE AVENUE, BOSTON
Confronta TNGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
1.915 | 164.76M | 42.51M | -116.49M | -120.82M | -1.12 |
|
ONC
Beigene Ltd Adr
|
241.85 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.94 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.31 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
590.33 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.93 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-17 | Iniziato | Jefferies | Buy |
| 2024-04-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Iniziato | Piper Sandler | Overweight |
| 2023-12-08 | Iniziato | B. Riley Securities | Buy |
| 2022-10-20 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Tango Therapeutics Inc Borsa (TNGX) Ultime notizie
Tango Therapeutics doses first subject in trial for MTAP-deleted tumours - Yahoo Finance
Tango Therapeutics starts trial for brain cancer drug By Investing.com - Investing.com South Africa
Tango Therapeutics Doses First Patient for Phase 1/2 Trial to Treat Brain Cancer - marketscreener.com
TNGX Initiates Phase 1/2 Trial for MTAP-Deleted Tumors | TNGX Stock News - GuruFocus
Tango Therapeutics Announces First Patient Dosed in TNG456 - GlobeNewswire
Tango Launches Phase 1/2 Trial for Brain Cancer Drug: New Hope for Deadly Glioblastoma Treatment - Stock Titan
Cantor Fitzgerald Issues Positive Estimate for TNGX Earnings - Defense World
Leerink Partnrs Analysts Boost Earnings Estimates for TNGX - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results - simplywall.st
Dimensional Fund Advisors LP Purchases 302,087 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates - MSN
Tango Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Tango Therapeutics, Inc. (NASDAQ:TNGX) Holdings Boosted by Wells Fargo & Company MN - Defense World
Tango Therapeutics Extends Cash Runway Amid Clinical Progress - TipRanks
Tango Therapeutics (TNGX) Plans $400 Million Mixed Securities Sh - GuruFocus
Tango Therapeutics Files For Mixed Shelf Of Up To $400 Million - marketscreener.com
Tango Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Tango Therapeutics Inc (TNGX) Q1 2025 Earnings: EPS of -$0.36 Mi - GuruFocus
TNGX Reports Q1 Revenue Miss, Advances Cancer Treatments | TNGX Stock News - GuruFocus
Tango Therapeutics, Inc. SEC 10-Q Report - TradingView
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewswire
Barclays PLC Has $307,000 Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics (TNGX) to Release Earnings on Monday - Defense World
Insights into Tango Therapeutics's Upcoming Earnings - Nasdaq
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of “Buy” by Analysts - Defense World
21,500 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Acquired by Renaissance Technologies LLC - Defense World
JPMorgan Chase & Co. Has $97,000 Stock Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study - Barchart.com
There is no way Tango Therapeutics Inc (TNGX) can keep these numbers up - Sete News
Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - GlobeNewswire
Is Tango Therapeutics Inc (TNGX) worth investing in despite its undervalued state? - uspostnews.com
Tango Therapeutics Inc (TNGX) Stock: A Year of Highs and Lows - investchronicle.com
Insider’s View: Deciphering Tango Therapeutics Inc (TNGX)’s Financial Health Through Ratios - DWinneX
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Geode Capital Management LLC - Defense World
Now Is The Time To Build A Position In Tango Therapeutics Inc (NASDAQ:TNGX) - Marketing Sentinel
Press Release Distribution & PR Platform - ACCESS Newswire
Gaining Ground: Tango Therapeutics Inc (TNGX) Closes Lower at 2.35, Down -0.42 - DWinneX
What is the investor’s view on Tango Therapeutics Inc (TNGX)? - uspostnews.com
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Franklin Resources Inc. - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $12.33 Average PT from Analysts - Defense World
Equities Analysts Offer Predictions for TNGX Q1 Earnings - Defense World
Tango Bypasses IPO Route With SPAC Merger - insights.citeline.com
What is HC Wainwright’s Estimate for TNGX Q1 Earnings? - Defense World
Tango Therapeutics’ (TNGX) Buy Rating Reaffirmed at HC Wainwright - Defense World
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Tango Therapeutics stock holds Buy rating, $13 target from H.C. Wainwright - Investing.com Canada
Tango Therapeutics stock holds Buy rating, $13 target from H.C. Wainwright By Investing.com - Investing.com South Africa
Little Excitement Around Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Revenues As Shares Take 28% Pounding - simplywall.st
Tango Therapeutics Inc Azioni (TNGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
17.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):